Plasticell

Proteomics firm Cellzome said this week it has won more than €2.3 million ($3.1 million) in grants funding its participation in three separate research projects.

Plasticell has developed "serum-free protocols that direct the differentiation of Stemnion's stem cells into hard-to-obtain lineages."

Plasticell has formed a spinout called Progenitor Labs, which will focus on regenerative drug discovery.

The British stem cell research tools firm plans to use the funds to expand its business development and marketing activities.

The collaboration involves using Sigma-Aldrich's CompoZr zinc finger nuclease technology and Plasticell's CombiCult high-throughput screening system.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.